Which of the following is the best to reduce incidence of macrovascular complications in type 2 diabetes?
**Core Concept**
The management of type 2 diabetes involves not only controlling hyperglycemia but also preventing the development of macrovascular complications, such as myocardial infarction and stroke. Macrovascular complications are a major cause of morbidity and mortality in patients with diabetes. The best treatment option to reduce the incidence of these complications involves addressing the underlying pathophysiology of atherosclerosis and inflammation.
**Why the Correct Answer is Right**
The correct answer is **metformin** because it not only improves glycemic control but also has anti-inflammatory and anti-atherogenic properties. Metformin activates AMP-activated protein kinase (AMPK), which inhibits the expression of genes involved in inflammation and atherosclerosis. Additionally, metformin has been shown to reduce the risk of cardiovascular events and mortality in patients with type 2 diabetes. This is likely due to its ability to improve endothelial function, reduce inflammation, and inhibit the proliferation of vascular smooth muscle cells.
**Why Each Wrong Option is Incorrect**
**Option A:** **Pioglitazone** is a thiazolidinedione that improves insulin sensitivity but can increase the risk of cardiovascular events due to its effects on fluid retention and increased risk of heart failure.
**Option B:** **Sulfonylureas** can cause hypoglycemia and weight gain, which may increase the risk of cardiovascular events.
**Option C:** **Glucagon-like peptide-1 (GLP-1) receptor agonists** can cause gastrointestinal side effects and may increase the risk of pancreatitis.
**Clinical Pearl / High-Yield Fact**
The EMPA-REG OUTCOME trial demonstrated that empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of cardiovascular events and mortality in patients with type 2 diabetes. This highlights the importance of considering the cardiovascular benefits of glucose-lowering therapies when selecting treatment options for patients with diabetes.
**Correct Answer:** C. Metformin